US-based global healthcare company Abbott (NYSE:ABT) announced on Thursday that it has signed a definitive agreement to acquire molecular diagnostics company Exact Sciences (NASDAQ:EXAS), allowing Abbott to enter and lead in fast-growing cancer diagnostics segments.
Under the terms of the agreement, Exact Sciences shareholders will receive USD105 per common share, representing a total equity value of approximately USD21bn and an estimated enterprise value of USD23bn. Abbott's financing will absorb Exact Sciences' net debt of around USD1.8bn.
Together, the two companies expect to accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages.
Closing is expected in the second quarter of 2026, subject to Exact Sciences shareholder approval as well as regulatory clearance and other customary closing conditions.
Both companies' boards of directors have unanimously approved the deal.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis